Case number 1:21-cv-01330
Novartis Pharmaceuticals Corporation v. Torrent Pharma Inc., et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Jul 18, 2024 | 269 | Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,096,918. (Attachments: # 1 Consent Judgment (redacted version))(nms) (Entered: 07/18/2024) (0) |
| Jul 12, 2024 | 267 | REDACTED VERSION of 265 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/14/2024 (nms). (Entered: 07/12/2024) (4) |
| Jul 12, 2024 | 268 | REDACTED VERSION of 266 Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/14/2024 (nms). (Entered: 07/12/2024) (4) |
| Jul 8, 2024 | 266 | [SEALED] Consent Judgment and Order of Injunction. Signed by Judge Richard G. Andrews on 7/8/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01794-RGA(nms) (Entered: 07/08/2024) (0) |
| Jul 5, 2024 | 265 | [SEALED] PROPOSED Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2024 (nms). (Entered: 07/05/2024) (0) |
| Jun 28, 2024 | 264 | REDACTED VERSION of 263 Consent Judgment, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,. (Taylor, Daniel) Modified on 6/28/2024 (nms). (Entered: 06/28/2024) (4) |
| Jun 21, 2024 | 263 | [SEALED] CONSENT JUDGMENT and Order of Injunction. Signed by Judge Richard G. Andrews on 6/21/2024.*This filing has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA(nms) (Entered: 06/21/2024) (0) |
| Jun 20, 2024 | 262 | Sur-Surreply Post-Trial Brief on the invalidity of U.S. Patent No. 11,058,667, by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Taylor, Daniel) Modified on 6/20/2024 (nms). (Entered: 06/20/2024) (3) |
| Jun 12, 2024 | 261 | REDACTED VERSION of 259 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/12/2024 (nms). (Entered: 06/12/2024) (4) |
| Jun 7, 2024 | 260 | POST-Trial Reply Brief on Invalidity of the '918 and '667 Patents, by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Taylor, Daniel) Modified on 6/9/2024 (nms). (Entered: 06/07/2024) (25) |
| Jun 4, 2024 | 259 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/4/2024 (nms). (Entered: 06/04/2024) (0) |
| May 16, 2024 | 258 | SO ORDERED Granting (D.I. 257 in 21-cv-1330-RGA; D.I. 160 in 21-cv-1760-RGA; D.I. 153 in 21-cv-1794-RGA; D.I. 1369 in 20-md-2930-RGA) STIPULATION and Proposed Order to Extend Time to submit Post-Trial Reply Briefs to June 7, 2024, and hyperlinked briefs to June 12, 2024. Signed by Judge Richard G. Andrews on 5/16/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 05/16/2024) (3) |
| May 15, 2024 | 257 | STIPULATION and Proposed Order to Extend Time - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Taylor, Daniel) Modified on 5/15/2024 (nms). (Entered: 05/15/2024) (3) |
| May 10, 2024 | 256 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding hyperlinked post-trial documents. (Silver, Daniel) Modified on 5/10/2024 (nms). (Entered: 05/10/2024) (1) |
| May 3, 2024 | 254 | POST TRIAL Answering Brief on the Validity of the '667 and '918 Patents, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2024 (nms). (Entered: 05/03/2024) (30) |
| May 3, 2024 | 255 | Proposed Findings of Fact by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 05/03/2024) (30) |
| Apr 4, 2024 | 250 | Official Transcript of Bench Trial held on 2/13/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/25/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/3/2024. (Triozzi, Heather) (Main Document 250 replaced on 4/17/2024) (nms). (Entered: 04/04/2024) (286) |
| Apr 4, 2024 | 251 | Official Transcript of Bench Trial held on 2/14/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/25/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/3/2024. (Triozzi, Heather) (Main Document 251 replaced on 4/17/2024) (nms). (Entered: 04/04/2024) (236) |
| Apr 4, 2024 | 252 | Official Transcript of Bench Trial held on 2/15/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/25/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/3/2024. (Triozzi, Heather) (Main Document 252 replaced on 4/17/2024) (nms). (Entered: 04/04/2024) (89) |
| Apr 4, 2024 | 253 | Official Transcript of Bench Trial held on 2/16/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/25/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/3/2024. (Triozzi, Heather) (Main Document 253 replaced on 4/17/2024) (nms). (Entered: 04/04/2024) (82) |
| Apr 3, 2024 | 248 | Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding electronic versions of post-trial documents. (Taylor, Daniel) Modified on 4/4/2024 (nms). (Entered: 04/03/2024) (1) |
| Apr 3, 2024 | 249 | Official Transcript of Bench Trial held on 2/12/24 before Judge Richard G. Andrews. Court Reporter Heather M. Triozzi,Email: Heather_Triozzi@ded.uscourts.gov. Transcript may be viewed at the court public terminal or order/purchased through the Court Reporter before the deadline for Release of Transcript Restriction. After that date, it may be obtained through PACER. Redaction Request due 4/24/2024. Redacted Transcript Deadline set for 5/6/2024. Release of Transcript Restriction set for 7/2/2024. (Triozzi, Heather) (Main Document 249 replaced on 4/17/2024) (nms). (Entered: 04/03/2024) (263) |
| Apr 2, 2024 | 247 | NOTICE of Lodging of Defendants' Trial Demonstrative Exhibits used at the Trial held from February 12, 2024 to February 16, 2024 by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd., Hetero USA Inc., (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Exhibit 8, # 9 Exhibit 9)(Taylor, Daniel) (Entered: 04/02/2024) (0) |
| Mar 27, 2024 | 245 | POST-Trial Brief regarding Invalidity of the '918 and '667 Patents, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Taylor, Daniel) Modified on 3/27/2024 (nms). (Main Document 245 replaced on 5/22/2024) (nms). (Entered: 03/27/2024) (30) |
| Mar 27, 2024 | 246 | Proposed Findings of Fact by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Taylor, Daniel) (Entered: 03/27/2024) (30) |
| Feb 28, 2024 | 243 | Exhibit List for Bench Trial held 2/12/2024 - 2/16/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA. (lah) (Entered: 02/28/2024) (19) |
| Feb 28, 2024 | 244 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., enclosing Joint Trial Exhibits and Plaintiff's Exhibits. (Silver, Daniel) Modified on 2/29/2024 (nms). (Entered: 02/28/2024) (1) |
| Feb 27, 2024 | 242 | REDACTED VERSION of 216 MOTION in Limine to Exclude Documents and Testimony on the Issue of the Invalidity of the '918 Patent, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Attachments: # 1 Exhibits 1-4)(Taylor, Daniel) Modified on 2/27/2024 (nms). (Entered: 02/27/2024) (0) |
| Feb 22, 2024 | 241 | STIPULATION and Proposed Order to Extend Time to submit public versions of Motion in Limine to Exclude Documents and Testimony on the Issue of the Invalidity of the '918 Patent (D.I. 1242 in 20md2930-RGA; D.I. 216 in 21cv1330-RGA) to February 28, 2024 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Taylor, Daniel) Modified on 2/23/2024 (nms). (Entered: 02/22/2024) (2) |
| Feb 21, 2024 | 238 | ORAL ORDER: The post-trial briefing schedule and limits submitted on 2/20/2024 (D.I. 128 in 21-cv-1794-RGA; D.I. 1271 in 20-md-2930-RGA; D.I. 237 in 21-cv-1330-RGA; D.I. 135 in 21-cv-1760-RGA) is APPROVED. Ordered by Judge Richard G. Andrews on 2/21/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 02/21/2024) (0) |
| Feb 21, 2024 | 239 | REDACTED VERSION of 215 Proposed Pretrial Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/21/2024 (nms). (Entered: 02/21/2024) (30) |
| Feb 21, 2024 | 240 | REDACTED VERSION of 219 MOTION in Limine to Preclude Dr. Steed, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibits)(Joyce, Alexandra) Modified on 2/21/2024 (nms). (Entered: 02/21/2024) (0) |
| Feb 20, 2024 | 237 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding post-trial briefing. (Silver, Daniel) Modified on 2/21/2024 (nms). (Entered: 02/20/2024) (1) |
| Feb 15, 2024 | 236 | REDACTED VERSION of 231 Sealed Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/15/2024 (nms). (Entered: 02/15/2024) (4) |
| Feb 9, 2024 | 234 | MOTION for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by MSN Laboratories Private Limited, MSN Life Sciences Private Limited, MSN Pharmaceuticals Inc.. (Weinblatt, Richard) (Entered: 02/09/2024) (3) |
| Feb 9, 2024 | 235 | ORAL ORDER: The Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices (D.I. 132 in 21-cv-1760-RGA; D.I. 126 in 21-cv-1794-RGA; D.I. 1264 in 20-md-2930-RGA; D.I. 234 in 21-cv-1330-RGA) is DENIED. Ordered by Judge Richard G. Andrews on 2/9/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 02/09/2024) (0) |
| Feb 8, 2024 | 227 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding experts curriculum vitae. (Attachments: # 1 Dr. Stuart Katz, # 2 Dr. Alexander M. Klibanov, # 3 Dr. Adam J. Matzger, # 4 Dr. Aeri Park, # 5 Dr. Francis Spinale, # 6 Dr. David R. Taft, # 7 Dr. Bernhardt Trout)(Silver, Daniel) Modified on 2/8/2024 (nms). (Entered: 02/08/2024) (0) |
| Feb 8, 2024 | 228 | Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding experts' curriculum vitae. (Attachments: # 1 Dr. David A. Atwood, # 2 Dr. Jonathan W. Steed, # 3 Dan James Fintel, M.D.)(Taylor, Daniel) Modified on 2/8/2024 (nms). (Entered: 02/08/2024) (0) |
| Feb 8, 2024 | 229 | Unopposed Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Silver, Daniel) Modified on 2/8/2024 (nms). (Entered: 02/08/2024) (0) |
| Feb 8, 2024 | 230 | ORDER Granting (D.I. 124 in 21-cv-1794-RGA; D.I. 128 in 21-cv-1760-RGA; D.I. 229 in 21-cv-1330-RGA; D.I. 1258 in 20-md-2930-RGA) Unopposed Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. Signed by Judge Richard G. Andrews on 2/8/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 02/08/2024) (2) |
| Feb 8, 2024 | 231 | [SEALED] STIPULATION and Proposed Order Narrowing Issues for Trial, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 2/8/2024 (nms). (Entered: 02/08/2024) (0) |
| Feb 8, 2024 | 232 | [SEALED] ORDER Granting (D.I. 1260 in 20-md-2930-RGA; D.I. 130 in 21-cv-1760-RGA; D.I. 231 in 21-cv-1330-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 2/8/2024.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA(nms) (Entered: 02/08/2024) (0) |
| Feb 8, 2024 | 233 | ORAL ORDER: The motion in limine (D.I. 217 in 21-cv-1330-RGA; D.I. 1243 in 20-md-2930-RGA) is DISMISSED as moot. Ordered by Judge Richard G. Andrews on 2/8/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 02/08/2024) (0) |
| Feb 7, 2024 | 226 | ORDER AFTER PRETRIAL CONFERENCE: The Proposed Pretrial Order (D.I. 1241) is ADOPTED, as modified by any discussion a the pretrial conference. A bench trial will begin on 2/12/2024, at 9:15 a.m. (see Order for further details). Signed by Judge Richard G. Andrews on 2/7/2024. (nms) (Entered: 02/07/2024) (2) |
| Feb 5, 2024 | 224 | Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding Hetero's identification of the relevant paragraphs of Dr. Steed's reply and subsequent expert reports that are relevant to the defense of infringement as to the '918 Patent and that Hetero may rely on for noninfringement purposes at trial. (Taylor, Daniel) Modified on 2/6/2024 (nms). (Entered: 02/05/2024) (2) |
| Feb 5, 2024 | 225 | STIPULATION and Proposed Order to Extend Time to file redacted versions of the Joint Proposed Pretrial Order, Defendants' Motion in Limine, and Novartis's Motion in Limine to February 21, 2024 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 2/6/2024 (nms). (Entered: 02/05/2024) (3) |
| Feb 1, 2024 | 223 | ORAL ORDER: The Parties are requested to provide the Court at the pretrial conference two copies each of the Park, Steed, and Atwood Reply Reports, the Park and Trout Sur-Reply Reports, the Steed and Atwood Sur-sur-Reply Reports, the Park Sur-sur-sur Reply Report, and the Steed Sur-sur-sur-sur-Reply Report. Ordered by Judge Richard G. Andrews on 2/1/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 02/01/2024) (0) |
| Jan 30, 2024 | 220 | Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, responding to Plaintiff's letter dated 1/29/2024. (Taylor, Daniel) Modified on 1/30/2024 (nms). (Entered: 01/30/2024) (2) |
| Jan 30, 2024 | 221 | Joint Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Proposed Order)(Joyce, Alexandra) Modified on 1/30/2024 (nms). (Entered: 01/30/2024) (0) |
| Jan 30, 2024 | 222 | SO ORDERED Granting (D.I. 1247 in 20-md-2930-RGA; D.I. 117 in 21-cv-1794-RGA; D.I. 120 in 21-cv-1760-RGA; D.I. 221 in 21-cv-1330-RGA) Joint Motion for Exemption of Persons from the District of Delaware's May 15, 2023 Standing Order on Personal Devices. Signed by Judge Richard G. Andrews on 1/30/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA, 1:21-cv-01794-RGA(nms) (Entered: 01/30/2024) (4) |
| Jan 29, 2024 | 215 | [SEALED] Proposed Pretrial Order by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Exhibit 1A, # 2 Exhibit 1B, # 3 Exhibit 2A, # 4 Exhibit 2B, # 5 Exhibit 3A, # 6 Exhibit 3B, # 7 Exhibit 4A, # 8 Exhibit 4B, # 9 Exhibit 5A, # 10 Exhibit 5B, # 11 Exhibit 6A, # 12 Exhibit 6B, # 13 Exhibit 7A, # 14 Exhibit 7B, # 15 Exhibit 8A, # 16 Exhibit 8B, # 17 Exhibit 9A, # 18 Exhibit 9B, # 19 Exhibit 10A, # 20 Exhibit 10B, # 21 Exhibit 11A, # 22 Exhibit 11B, # 23 Exhibit 12A, # 24 Exhibit 12B)(Silver, Daniel) (Entered: 01/29/2024) (0) |
| Jan 29, 2024 | 216 | [SEALED] MOTION in Limine to Exclude Documents and Testimony on the Issue of the Invalidity of the '918 Patent - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Attachments: # 1 Exhibits 1-4, # 2 Certificate of Service)(Taylor, Daniel) Modified on 1/30/2024 (nms). (Entered: 01/29/2024) (0) |
| Jan 29, 2024 | 217 | Motion in Limine to Preclude Hetero from Relying on Reply and Sur-Surreply Validity Opinions to Rebut Novartis's Infringement Position - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 1/30/2024 (nms). (Additional attachment(s) added on 1/30/2024: # 2 Exhibit A) (nms). (Entered: 01/29/2024) (0) |
| Jan 29, 2024 | 219 | [SEALED] MOTION in Limine to Preclude Dr. Steed from Contradicting Inventor and Novartis Fact Testimony Concerning Possession of the Invention - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 1/30/2024 (nms). (Additional attachment(s) added on 1/30/2024: # 2 Exhibits 1-8) (nms). (Entered: 01/29/2024) (0) |
| Jan 19, 2024 | 214 | REDACTED VERSION of 203 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 1/22/2024 (nms). (Entered: 01/19/2024) (30) |
| Jan 17, 2024 | 213 | ORAL ORDER: The redactions filed at D.I. 1231 in 20md2920-RGA and at D.I. 210 in 21cv1330-RGA are accepted, with one exception. The first redaction on D.I. 1231 at 2 of 118 is rejected. The disclosure of the redacted sentence cannot harm Novartis. A revised redacted version consistent with this Order is due no later than three (3) days from the date of this Order. Ordered by Judge Richard G. Andrews on 1/17/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 01/17/2024) (0) |
| Jan 2, 2024 | 212 | ORAL ORDER: The Court has considered the parties letter. (20md2930, D.I. 1226). The Court will allocate twenty-five hours for trial spread out over the five days of the week beginning February 12, 2024 (assuming that Mylan intends to try its case in Delaware rather than West Virginia). Novartis is to reduce the number of asserted claims to no more than four by January 16, 2024. Defendants are to reduce the number of defenses to no more than three (not counting non-infringement) per asserted claim by January 22, 2024, with any specific asserted obviousness combination counting as one defense. The Court will discuss the structure of the trial with the parties at the pretrial conference on February 2, 2024. Ordered by Judge Richard G. Andrews on 1/2/2024. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 01/02/2024) (0) |
| Dec 29, 2023 | 210 | REDACTED VERSION of 203 Letter, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/29/2023 (nms). (Entered: 12/29/2023) (30) |
| Dec 29, 2023 | 211 | Letter to The Honorable Richard G. Andrews, from Daniel M. Silver, Esq., regarding Novartis's request for redactions and supporting declaration. (Attachments: # 1 Declaration)(Silver, Daniel) Modified on 12/29/2023 (nms). (Entered: 12/29/2023) (0) |
| Dec 21, 2023 | 209 | ORAL ORDER: The redacted filing (D.I. 208 ) is REJECTED because parts of it are redacted in its entirety. Absent a compelling reason, supported by a statement under oath by a party, redactions in their entirety are impermissible; redactions must be done so as to redact the least possible amount of the materials submitted. Failure to make a good faith attempt at such redactions may result in sanctions, the most common of which would be simply unsealing the entire filing. Redacting in its entirety a document, or parts of it, that contains publicly available materials is prima facie evidence of bad faith. A revised redacted filing is DUE within five business days. Ordered by Judge Richard G. Andrews on 12/21/2023. (nms) (Entered: 12/21/2023) (0) |
| Dec 20, 2023 | 208 | REDACTED VERSION of 203 Letter, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7)(Taylor, Daniel) Modified on 12/21/2023 (nms). (Entered: 12/20/2023) (0) |
| Dec 18, 2023 | 206 | REDACTED VERSION of 202 Letter, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/18/2023 (nms). (Entered: 12/18/2023) (30) |
| Dec 18, 2023 | 207 | Joint letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding trials for the '667 & '918 patents. (Taylor, Daniel) Modified on 12/19/2023 (nms). (Entered: 12/18/2023) (3) |
| Dec 14, 2023 | 204 | ORDER DENYING NOVARTIS'S MOTION TO PRECLUDE: The motion is DENIED (D.I. 202 in 21-cv-1330-RGA; D.I. 1217 in 20-md-2930-RGA). Dr. Park is permitted to file a report, limited to no more than 250 words, in response to paragraph 8, and Dr. Steed is permitted to file a report, also limited to no more than 250 words, responding to Dr. Park's aforementioned report. There will be no further deposition of Dr. Park. The parties shall promptly meet and confer and agree to a timetable for the submission of the two 250-word maximum reports. Signed by Judge Richard G. Andrews on 12/14/2023. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 12/14/2023) (2) |
| Dec 14, 2023 | 205 | ORAL ORDER; The conference scheduled for 1/3/2024, is CANCELED. Ordered by Judge Richard G. Andrews on 12/14/2023. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 12/14/2023) (0) |
| Dec 13, 2023 | 203 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel A. Taylor, regarding Defendants' opposition to Plaintiff's request to strike. (Attachments: # 1 Exhibit 1, # 2 Exhibit 2, # 3 Exhibit 3, # 4 Exhibit 4, # 5 Exhibit 5, # 6 Exhibit 6, # 7 Exhibit 7, # 8 Proposed Order, # 9 Certificate of Service)(Taylor, Daniel) Modified on 12/13/2023 (nms). (Entered: 12/13/2023) (0) |
| Dec 11, 2023 | 202 | [SEALED] Letter to The Honorable Richard G. Andrews, from Daniel M. Silver on behalf of Plaintiff, regarding discovery dispute. (Attachments: # 1 Exhibits A-D, # 2 Proposed Order, # 3 Certificate of Service)(Silver, Daniel) Modified on 12/11/2023 (nms). (Entered: 12/11/2023) (0) |
| Dec 8, 2023 | 201 | ORAL ORDER: The parties have advised that a dispute has arisen requiring attention. The Court will hold a discovery conference on 1/3/2024, at 10:00 AM in Courtroom 6A. In preparation for this conference the parties shall follow the Discovery Matters and Disputes procedure as set forth in the Scheduling Order. Ordered by Judge Richard G. Andrews on 12/8/2023. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 12/08/2023) (0) |
| Nov 22, 2023 | 200 | NOTICE OF SERVICE of Defendants Hetero USA, Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Torrent Pharma Inc., and Torrent Pharmaceuticals Ltd.'s Sur-Reply Expert of Jonathan W. Steed, Ph.D. on the invalidity of the '918 Patent and the Sur-Reply Expert Report of David A. Atwood, Ph.D. on U.S. Patent No. 11,096,918 filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,.(Taylor, Daniel) (Entered: 11/22/2023) (2) |
| Nov 6, 2023 | 198 | NOTICE OF SERVICE of Defendants Hetero USA, Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Torrent Pharma Inc., and Torrent Pharmaceuticals Ltd.'s Highly Confidential Reply Expert of Jonathan W. Steed, Ph.D. on the invalidity of the '918 Patent and the Reply Expert Report of David A. Atwood, Ph.D. on U.S. Patent No. 11,096,918 filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,.(Taylor, Daniel) (Entered: 11/06/2023) (2) |
| Nov 6, 2023 | 199 | NOTICE OF SERVICE of (1) Reply Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III and (2) Reply Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 11/06/2023) (2) |
| Sep 19, 2023 | 197 | NOTICE OF SERVICE of Novartis's Objections and Responses to Defendants' 2nd Set of Requests for Admission to Plaintiff Novartis Pharmaceuticals Corp. to Establish the Authenticity of Documents or to Establish Documents as Business Records filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/19/2023) (2) |
| Sep 11, 2023 | 195 | NOTICE OF SERVICE of Responsive Expert Report of Bernhardt L. Trout, Ph.D. on the Validity of U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/11/2023) (2) |
| Sep 11, 2023 | 196 | NOTICE OF SERVICE of Defendants Hetero USA, Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III's Highly Confidential Responsive Expert of Jonathan W. Steed, Ph.D. on non-infringement of the '918 Patent filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,.(Taylor, Daniel) (Entered: 09/11/2023) (2) |
| Aug 18, 2023 | 193 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Torrent Pharma Inc., and Torrent Pharmaceuticals Ltd.'s 2nd Set of Requests for Admissions (Nos. 1-5) to Plaintiff Novartis Pharmaceuticals Corporation to establish the authenticity of documents or establish documents as business records, regarding U.S. Patent No. 11,096,918 ("the '918 patent") filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,.(Belgam, Neal) (Entered: 08/18/2023) (2) |
| Aug 18, 2023 | 194 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited & Hetero Labs Limited Unit III's Highly Confidential Supplemental Objections and Responses to Plaintiff Novartis Pharmaceuticals Corporation's First Set of Interrogatories (Nos. 1-3), regarding U.S. Patent No. 11,096,918 ("the '918 patent") filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,.(Belgam, Neal) (Entered: 08/18/2023) (2) |
| Aug 17, 2023 | 192 | NOTICE OF SERVICE of Supplemental Opening Expert Reports of Adam J. Matzger, Ph.D. filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/17/2023) (3) |
| Jul 31, 2023 | 190 | NOTICE OF SERVICE of (1) Expert Report of Adam J. Matzger, Ph.D. on Infringement of U.S. Patent No. 11,096,918 by Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III, and (2) Expert Report of Aeri Park, Ph.D. on U.S. Patent No. 11,096,918 filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 07/31/2023) (3) |
| Jul 31, 2023 | 191 | NOTICE OF SERVICE of Defendants Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA, Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III's Highly Confidential Opening Expert of Jonathan W. Steed, Ph.D. filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,.(Taylor, Daniel) (Entered: 07/31/2023) (2) |
| Jul 26, 2023 | 188 | REDACTED VERSION of 184 Proposed Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/26/2023 (nms). (Entered: 07/26/2023) (3) |
| Jul 26, 2023 | 189 | REDACTED VERSION of 187 Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/26/2023 (nms). (Entered: 07/26/2023) (3) |
| Jul 21, 2023 | 187 | [SEALED] ORDER Granting (D.I. 1115 in 20-md-2930-RGA; D.I. 184 in 21-cv-1330-RGA) Stipulation and Proposed Order between Plaintiff and Torrent Defendants. Signed by Judge Richard G. Andrews on 7/21/2023.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 07/21/2023) (0) |
| Jul 20, 2023 | 184 | [SEALED] Stipulation and Proposed Order between Plaintiff and Torrent Defendants, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/20/2023 (nms). (Entered: 07/20/2023) (0) |
| Jul 20, 2023 | 185 | REDACTED VERSION of 182 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/21/2023 (nms). (Entered: 07/20/2023) (4) |
| Jul 20, 2023 | 186 | REDACTED VERSION of 183 Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/21/2023 (nms). (Entered: 07/20/2023) (4) |
| Jul 13, 2023 | 182 | [SEALED] Proposed Consent Judgment and Order of Injunction betwen Plaintiff and Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc., by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/13/2023 (nms). (Entered: 07/13/2023) (0) |
| Jul 13, 2023 | 183 | [SEALED] Consent Judgement and Order of Injunction between Plaintiff and Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.. Signed by Judge Richard G. Andrews on 7/13/2023.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02021-RGA, 1:21-cv-01330-RGA(nms) (Entered: 07/13/2023) (0) |
| Jul 12, 2023 | 181 | STIPULATION and Proposed Order to Extend Time regarding expert reports - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 7/12/2023 (nms). (Entered: 07/12/2023) (3) |
| Jul 7, 2023 | 180 | REDACTED VERSION of 176 Stipulation and Proposed Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/7/2023 (nms). (Entered: 07/07/2023) (6) |
| Jul 5, 2023 | 178 | REDACTED VERSION of 171 Stipulation and Proposed Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/6/2023 (nms). (Entered: 07/05/2023) (4) |
| Jul 5, 2023 | 179 | REDACTED VERSION of 174 Stipulation and Proposed Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/6/2023 (nms). (Entered: 07/05/2023) (4) |
| Jun 30, 2023 | 175 | [SEALED] ORDER Granting (1089 in 20-md-2930-RGA; 89 in 21-cv-1760-RGA; 399 in 19-cv-2053-RGA; 174 in 21-cv-1330-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 6/30/2023.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA, 1:21-cv-01330-RGA, 1:21-cv-01760-RGA(nms) (Entered: 06/30/2023) (0) |
| Jun 30, 2023 | 176 | [SEALED] STIPULATION and [Proposed] Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/30/2023 (nms). (Entered: 06/30/2023) (0) |
| Jun 30, 2023 | 177 | [SEALED] ORDER Granting (16 in 23-cv-401-RGA; 82 in 22-cv-1395-RGA; 176 in 21-cv-1330-RGA; 1091 in 20-md-2930-RGA; 95 in 22-cv-451-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 6/30/2023.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:22-cv-00451-RGA, 1:22-cv-01395-RGA, 1:23-cv-00401-RGA(nms) (Entered: 06/30/2023) (0) |
| Jun 29, 2023 | 172 | [SEALED] ORDER Granting (D.I. 642 in 19-cv-1979-RGA; D.I. 171 in 21-cv-1330-RGA; D.I. 1086 in 20-md-2930-RGA; D.I. 86 in 21-cv-1794-RGA) Stipulation and Proposed Order. Signed by Judge Richard G. Andrews on 6/29/2023.*This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:21-cv-01330-RGA, 1:21-cv-01794-RGA(nms) (Entered: 06/29/2023) (0) |
| Jun 29, 2023 | 173 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Main Document) (4) |
| Jun 29, 2023 | 174 | [SEALED] STIPULATION and [Proposed] Order by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/29/2023) (0) |
| Jun 29, 2023 | 173 | MOTION for Pro Hac Vice Appearance of Attorney Melinda R. Roberts - filed by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certification for Melinda R. Roberts)(Silver, Daniel) (Entered: 06/29/2023) (Certification for Melinda R. Roberts) (1) |
| Jun 28, 2023 | 170 | NOTICE OF SERVICE of Novartis's Second Supplemental Objections and Responses to Defendants' Common Interrogatories Nos. 2, 5 and 6 (918 Patent) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/28/2023) (3) |
| Jun 28, 2023 | 171 | [SEALED] STIPULATION and [Proposed] Order by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 06/28/2023) (0) |
| Jun 14, 2023 | 168 | STIPULATION with Respect to Authenticity of Documents between Plaintiff and Macleods Defendants, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/14/2023 (nms). (Entered: 06/14/2023) (4) |
| Jun 14, 2023 | 169 | STIPULATION with Respect to Authenticity of Documents between Plaintiff and Hetero and Torrent Defendants, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 6/14/2023 (nms). (Entered: 06/14/2023) (4) |
| Jun 12, 2023 | 167 | NOTICE OF SERVICE of (1) Novartis Objections and Responses to Defendants Highly Confidential Attorneys Eyes Only First Set of Individual Requests for Admission to Plaintiff Novartis Pharmaceuticals Corporation (Nos. 1-10) (667 Patent), (2) Plaintiff's Objections and Responses to Defendants First Set of Individual Requests for Admissions (Nos. 1-8) (918 Patent), and (3) Plaintiff's Objections and Responses to Defendants' First Set of Requests for Admissions (Nos. 1-24) (918 Patent) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 06/12/2023) (5) |
| Jun 5, 2023 | 165 | NOTICE to Take Deposition of Peter Waibel on June 14, 2023 filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,.(Taylor, Daniel) (Entered: 06/05/2023) (3) |
| Jun 5, 2023 | 166 | NOTICE to Take Deposition of Michael Motto, Ph.D. on June 23, 2023 filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,.(Taylor, Daniel) (Entered: 06/05/2023) (3) |
| May 30, 2023 | 164 | NOTICE OF SERVICE of Novartis's Second Supplemental Objections and Responses to Defendants' First Set of Common Interrogatories for the '918 Patent filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 05/30/2023) (4) |
| May 24, 2023 | 161 | NOTICE OF SERVICE of Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's First Set of Requests for Admission (Nos. 1-21) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) (Entered: 05/24/2023) (2) |
| May 24, 2023 | 162 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited and Hetero Labs Limited Unit III's Highly Confidential Objections and Responses to Plaintiff Novartis Pharmaceutical Corporation's First Set of Requests for Admissions (Nos. 1-19) filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,.(Taylor, Daniel) (Entered: 05/24/2023) (2) |
| May 24, 2023 | 163 | NOTICE OF SERVICE of Defendants Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Highly Confidential Objections and Responses to Plaintiff Novartis Pharmaceutical Corporation's First Set of Requests for Admissions (Nos. 1-19) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 05/24/2023) (2) |
| May 22, 2023 | 159 | NOTICE OF SERVICE of Plaintiff's Second Supplemental Infringement Chart for U.S. Patent No. 11,096,918 Against Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/22/2023) (4) |
| May 22, 2023 | 160 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Requests for Admissions to Establish the Authenticity of Documents or Establish Documents as Business Records to Plaintiff Novartis Pharmaceuticals Corporation filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,.(Taylor, Daniel) (Entered: 05/22/2023) (2) |
| May 19, 2023 | 158 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc., Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Highly Confidential Invalidity Contentions to Plaintiff Novartis Pharmaceutical Corporation filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Taylor, Daniel) (Entered: 05/19/2023) (2) |
| May 17, 2023 | 154 | NOTICE OF SERVICE of Novartis's Requests for Admissions to Defendants to Establish the Authenticity of Documents of Establish Documents as Business Records filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/17/2023) (4) |
| May 17, 2023 | 155 | NOTICE of Deposition Under Fed. R. Civ. P. 30(b)(6) to Hetero USA Inc., Hetero Lab Limited, and Hetero Labs Limited Unit III by Novartis Pharmaceuticals Corporation (Joyce, Alexandra) (Entered: 05/17/2023) (5) |
| May 17, 2023 | 156 | NOTICE of Deposition Under Fed. R. Civ. P. 30(b)(6) to Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc. by Novartis Pharmaceuticals Corporation (Joyce, Alexandra) (Entered: 05/17/2023) (5) |
| May 17, 2023 | 157 | NOTICE of Deposition Under Fed. R. Civ. P. 30(b)(6) to Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd. by Novartis Pharmaceuticals Corporation (Joyce, Alexandra) (Entered: 05/17/2023) (5) |
| May 15, 2023 | 153 | NOTICE OF SERVICE of (1) Novartis's Supplemental Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-8) and (2) Novartis's Objections and Responses to Defendants' Notice of Deposition to Novartis Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 05/15/2023) (3) |
| May 10, 2023 | 151 | NOTICE OF SERVICE of Defendants' Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Macleods Pharmaceuticals Ltd., and Macleods Pharma USA, Inc.'s First Set of Requests for Admissions (Nos. 1-24) to Plaintiff Novartis Pharmaceutical Corporation filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,.(Taylor, Daniel) (Entered: 05/10/2023) (2) |
| May 10, 2023 | 152 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited and Hetero Labs Limited Unit III's Highly Confidential First Set of Individual Requests for Admission (Nos. 1-8) to Plaintiff Novartis Pharmaceutical Corporation filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,.(Taylor, Daniel) (Entered: 05/10/2023) (2) |
| May 3, 2023 | 150 | REDACTED VERSION of 148 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2023 (nms). (Entered: 05/03/2023) (5) |
| Apr 26, 2023 | 148 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/26/2023 (nms). (Entered: 04/26/2023) (0) |
| Apr 26, 2023 | 149 | [SEALED] Consent Judgment and Order of Injunction (between Dr. Reddy's Laboratories Inc., Dr. Reddy's Laboratories Ltd. and Novartis Pharmaceuticals Corporation). Signed by Judge Richard G. Andrews on 4/26/2023.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-02053-RGA, 1:21-cv-01330-RGA, 1:22-cv-00498-RGA(nms) (Entered: 04/26/2023) (0) |
| Apr 24, 2023 | 147 | NOTICE OF SERVICE of Novartis's First Set of Requests for Admissions to Defendants filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 04/24/2023) (3) |
| Apr 21, 2023 | 146 | REDACTED VERSION of 141 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/21/2023 (nms). (Entered: 04/21/2023) (5) |
| Apr 17, 2023 | 145 | NOTICE OF SERVICE of Defendants' Notice of Deposition Pursuant to Fed. R. Civ. P. 30(b)(6) filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,.(Belgam, Neal) (Entered: 04/17/2023) (2) |
| Apr 14, 2023 | 143 | NOTICE of Appearance by Daniel Taylor on behalf of Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc. (Taylor, Daniel) (Entered: 04/14/2023) (2) |
| Apr 14, 2023 | 144 | NOTICE of Appearance by Daniel Taylor on behalf of Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. (Taylor, Daniel) (Entered: 04/14/2023) (2) |
| Apr 11, 2023 | 141 | [SEALED] Proposed Consent Judgment and Order of Injunction, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 4/11/2023 (nms). (Entered: 04/11/2023) (0) |
| Apr 11, 2023 | 142 | [SEALED] Consent Judgment and Order of Injunction between Plaintiff and Aurobindo Pharma Ltd. and Aurobindo Pharma USA Inc.. Signed by Judge Richard G. Andrews on 4/11/2023.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:21-cv-01330-RGA, 1:21-cv-01407-RGA(nms) (Entered: 04/11/2023) (0) |
| Mar 17, 2023 | 140 | NOTICE of Withdrawal of Appearance of Delaware Counsel, Eve Ormerod by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Hetero USA Inc., (Ormerod, Eve) (Entered: 03/17/2023) (3) |
| Feb 16, 2023 | 136 | NOTICE OF SERVICE of Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.s Objections and Responses to Novartiss First Set of Requests for the Production of Documents and Things (Nos. 53-56) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) (Entered: 02/16/2023) (2) |
| Feb 16, 2023 | 137 | NOTICE OF SERVICE of Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III's Objections and Responses to Plaintiff's Second Set of Requests for the Production of Documents and Things (No. 53-56) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.,.(Ormerod, Eve) (Entered: 02/16/2023) (2) |
| Feb 16, 2023 | 138 | NOTICE OF SERVICE of Defendants, Aurobindo Pharma Ltd. and Aurobindo Pharma USA, Inc's Responses and Objections to Plaintiff's Second Set of Requests for Production of Documents and Things (Nos. 53-56) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Myer, R.) (Entered: 02/16/2023) (2) |
| Feb 16, 2023 | 139 | NOTICE OF SERVICE of Dr. Reddys Laboratories, Inc. and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss Second Set of Requests for the Production of Documents and Things (Nos. 53-56)(918 Patent) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd..(Stamoulis, Stamatios) (Entered: 02/16/2023) (2) |
| Jan 24, 2023 | 135 | MOTION for Pro Hac Vice Appearance of Attorney Timothy H. Kratz and Michael P. Hogan - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Myer, R.) (Entered: 01/24/2023) (6) |
| Jan 19, 2023 | 134 | NOTICE OF SUBSTITUTION OF COUNSEL re Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.: Entry of appearance of attorney R. Touhey Myer. Attorney Kenneth L. Dorsney, Cortlan S. Hitch terminated. (Myer, R.) (Entered: 01/19/2023) (3) |
| Jan 18, 2023 | 133 | NOTICE OF SERVICE of Novartis's Second Set of Requests to Defendants for the Production of Documents and Things filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 01/18/2023) (5) |
| Dec 30, 2022 | 131 | SO ORDERED Granting (D.I. 130 in 21-cv-1330-RGA; D.I. 934 in 20-md-2930-RGA) Joint Stipulation and Proposed Order Regarding Claim Construction for U.S. Patent No. 11,096,918. Signed by Judge Richard G. Andrews on 12/30/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 12/30/2022) (5) |
| Dec 30, 2022 | 132 | [SEALED] ORDER Granting (D.I. 932 in 20-md-2930-RGA; D.I. 128 in 21-cv-1330-RGA; D.I. 42 in 21-cv-1407-RGA) STIPULATION to Extend Time. Signed by Judge Richard G. Andrews on 12/30/2022.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA, 1:21-cv-01407-RGA(nms) (Entered: 12/30/2022) (0) |
| Dec 28, 2022 | 130 | Joint Stipulation and Proposed Order Regarding Claim Construction for U.S. Patent No. 11,096,918, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 12/28/2022 (nms). (Entered: 12/28/2022) (5) |
| Dec 21, 2022 | 128 | [SEALED] STIPULATION to Extend the Deadline to Substantially Complete Document Production to February 17, 2023 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/21/2022 (nms). (Entered: 12/21/2022) (0) |
| Dec 21, 2022 | 129 | REDACTED VERSION of 128 STIPULATION to Extend the Deadline to Substantially Complete Document Production to February 17, 2023, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 12/21/2022 (nms). (Entered: 12/21/2022) (3) |
| Dec 15, 2022 | 126 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s First Set of Individual Interrogatories (Nos. 1-3) (C.A. No. 22-498-RGA), and (2) Novartis's Objections and Responses to Defendants Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd.'s First Set of Individual Interrogatories (Nos. 1-2) (C.A. No. 21-1330-RGA) filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (3) |
| Dec 15, 2022 | 127 | NOTICE OF SERVICE of (1) Novartis's Objections and Responses to Defendants' First Set of Joint Requests for the Production of Documents and Things (Nos. 1-38) regarding the '918 patent, and (2) Novartis's Objections and Responses to Defendants' First Set of Common Interrogatories (Nos. 1-8) regarding the '918 patent filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 12/15/2022) (5) |
| Dec 12, 2022 | 125 | NOTICE OF SERVICE of Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s First Supplemental Objections and Responses to Novartis's First Set of Requests for the Production of Documents and Things (Nos. 1-52) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Ferraro, April) (Entered: 12/12/2022) (2) |
| Dec 6, 2022 | 124 | STIPULATION TO EXTEND TIME the Deadline to Substantially Complete Document Production to January 18, 2023 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) (Entered: 12/06/2022) (7) |
| Nov 28, 2022 | 123 | REDACTED VERSION of 120 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/29/2022 (nms). (Entered: 11/28/2022) (5) |
| Nov 22, 2022 | 122 | NOTICE OF SERVICE of Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s First Supplemental Objections and Responses to Novartiss First Set of Interrogatories (Nos. 1-3) [918 patent] filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) (Entered: 11/22/2022) (2) |
| Nov 21, 2022 | 121 | [SEALED] CONSENT JUDGMENT and Order of Injunction between Plaintiff and Defendant "Alkem. Signed by Judge Richard G. Andrews on 11/21/2022.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:21-cv-01330-RGA, 1:22-cv-00032-RGA(nms) (Entered: 11/21/2022) (0) |
| Nov 18, 2022 | 120 | [SEALED] PROPOSED Consent Judgment and Order of Injunction as to Alkem, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 11/21/2022 (nms). (Entered: 11/18/2022) (0) |
| Nov 14, 2022 | 118 | NOTICE OF SERVICE of Aurobindo's response to Plaintiff's Second Set of Interrogatories re the 918 Patent (Nos. 4-5) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth) (Entered: 11/14/2022) (3) |
| Nov 14, 2022 | 119 | NOTICE OF SERVICE of Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s First Set of Individual Interrogatories (Nos. 1-2) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) (Entered: 11/14/2022) (2) |
| Nov 8, 2022 | 115 | NOTICE OF SERVICE of (i) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's Second Set of Interrogatories (No. 4) and (ii) this Notice of Service filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) (Entered: 11/08/2022) (2) |
| Nov 8, 2022 | 116 | NOTICE OF SERVICE of Hetero USA, Inc., Hetero Labs Limited, and Hetero Labs Limited Unit IIIs Objections and Responses to Novartis Second set of Interrogatories (Nos. 4-5) filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,.(Ormerod, Eve) (Entered: 11/08/2022) (2) |
| Nov 8, 2022 | 117 | NOTICE OF SERVICE of Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.s Objections and Responses to Novartis Second set of Interrogatories (Nos. 4-5) filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) (Entered: 11/08/2022) (2) |
| Nov 7, 2022 | 114 | NOTICE OF SERVICE of Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s Responses to Novartiss Second Set of Interrogatories (Nos. 4-5) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) (Entered: 11/07/2022) (2) |
| Oct 7, 2022 | 113 | NOTICE OF SERVICE of Novartis's Second Set of Interrogatories to Defendants filed by Novartis Pharmaceuticals Corporation.(Silver, Daniel) (Entered: 10/07/2022) (10) |
| Sep 27, 2022 | 111 | MEMORANDUM OPINION. Signed by Judge Richard G. Andrews on 9/27/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 09/27/2022) (14) |
| Sep 27, 2022 | 112 | ORDER: Plaintiff's motions to dismiss the declaratory judgment counterclaims of invalidity and non-infringement against Plaintiff's U.S. Patents Nos. 9,517,226, 9,937,143, and 11,135,192 (D.I. 37, D.I. 40) are GRANTED. The counterclaims are DISMISSED without prejudice. Signed by Judge Richard G. Andrews on 9/27/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 09/27/2022) (2) |
| Sep 23, 2022 | 110 | NOTICE of Supplemental Information Relating to Torrent's & Hetero's Oppositions to Novartis's Motion to Dismiss Counterclaims Regarding the '226, '143 & '192 Patents by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc., (Attachments: # 1 Exhibit 1)(Ormerod, Eve) (Entered: 09/23/2022) (Main Document) (2) |
| Sep 23, 2022 | 110 | NOTICE of Supplemental Information Relating to Torrent's & Hetero's Oppositions to Novartis's Motion to Dismiss Counterclaims Regarding the '226, '143 & '192 Patents by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc., (Attachments: # 1 Exhibit 1)(Ormerod, Eve) (Entered: 09/23/2022) (Exhibit 1) (30) |
| Sep 22, 2022 | 109 | REDACTED VERSION of 107 Proposed Consent Judgment, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 9/23/2022 (nms). (Entered: 09/22/2022) (6) |
| Sep 16, 2022 | 108 | [SEALED] CONSENT JUDGMENT and Order of Injunction as relating to Defendant Laurus. Signed by Judge Richard G. Andrews on 9/16/2022.This order has been emailed to local counsel. Associated Cases: 1:20-md-02930-RGA, 1:19-cv-01979-RGA, 1:21-cv-01330-RGA, 1:22-cv-00186-RGA(nms) (Entered: 09/16/2022) (0) |
| Sep 15, 2022 | 107 | [SEALED] Proposed Consent Judgment and Order of Injunction as to Defendant Laurus, by Novartis Pharmaceuticals Corporation. (Attachments: # 1 Certificate of Service)(Silver, Daniel) Modified on 9/15/2022 (nms). (Entered: 09/15/2022) (0) |
| Sep 9, 2022 | 106 | NOTICE OF SERVICE of Defendants Joint Initial Invalidity Contentions filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) (Entered: 09/09/2022) (2) |
| Sep 7, 2022 | 96 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited and Hetero Labs Limited Unit III's Rule 26(a) Initial Disclosures and Paragraph 3 Disclosures filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Hetero USA Inc.,.(Ormerod, Eve) (Entered: 09/07/2022) (2) |
| Sep 7, 2022 | 97 | NOTICE OF SERVICE of Defendants Torrent Pharma, Inc. and Torrent Pharmaceuticals, Ltd.'s Rule 26(a) Initial Disclosures and Paragraph 3 Disclosures filed by Torrent Pharma Inc., Torrent Pharmaceticals Ltd., Torrent Pharmaceuticals Ltd..(Ormerod, Eve) (Entered: 09/07/2022) (2) |
| Sep 7, 2022 | 98 | NOTICE OF SERVICE of (i) Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Rule 26(a)(1) Initial Disclosures; and (ii) Defendants Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Disclosures Pursuant to Paragraph 3 of The Default Standard for Discovery filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Ferraro, April) (Entered: 09/07/2022) (4) |
| Sep 7, 2022 | 99 | NOTICE OF SERVICE of (1) Aurobindo's 26(a) Initial Disclosures for the '918 Patent; (2) Aurobindo's Paragraph 3 Disclosures for the '918 Patent; (3) Aurobindo's 26(a) Initial Disclosures for the '667 Patent and; (4) Aurobindo's Paragraph 3 Disclosures for the '667 Patent filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth) (Entered: 09/07/2022) (3) |
| Sep 7, 2022 | 100 | NOTICE OF SERVICE of (1) Plaintiff's Rule 26(a)(1) Initial Disclosures, and (2) Plaintiff's Initial Paragraph 3 Disclosures Regarding Electronic Systems Information filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 09/07/2022) (14) |
| Sep 7, 2022 | 101 | NOTICE OF SERVICE of 1) Defendants Laurus Labs Limited and Laurus Generics Inc.'s Responses and Objections to Plaintiff's First Set of Interrogatories (Nos. 1-3) and 2) Defendants Laurus Labs Limited and Laurus Generics Inc.'s Responses and Objections to Plaintiff's First Set of Requests for Production (Nos. 1-52) filed by Laurus Generics Inc., Laurus Labs Limited.(Poff, Adam) (Entered: 09/07/2022) (3) |
| Sep 7, 2022 | 102 | NOTICE OF SERVICE of (1) Aurobindo's response to Plaintiff's First Set of Interrogatories re the 918 Patent (Nos. 1-3); and (2) Aurobindo's response to Plaintiff's First Set of Requests for Production re the 918 Patent (Nos. 1-52) filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc..(Dorsney, Kenneth) (Entered: 09/07/2022) (2) |
| Sep 7, 2022 | 103 | NOTICE OF SERVICE of Defendants Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Torrent Pharma Inc. and Torrent Pharmaceuticals Ltd.'s Objections and Responses to Plaintiff Novartis First Set of Interrogatories and First Set of Requests for the Production of Documents and Things filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,.(Ormerod, Eve) (Entered: 09/07/2022) (2) |
| Sep 7, 2022 | 104 | NOTICE OF SERVICE of (i) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's First Set of Requests for the Production of Documents and Things (Nos. 1-52) and (ii) Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc.'s Objections and Responses to Novartis's First Set of Interrogatories (Nos. 1-3) filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd..(Seaman, John) (Entered: 09/07/2022) (4) |
| Sep 7, 2022 | 105 | NOTICE OF SERVICE of (1) Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss First Set of Requests for the Production of Documents and Things (Nos. 1-52)(918 Patent) and (2) Dr. Reddys Laboratories Inc. and Dr. Reddys Laboratories, Ltd.s Objections and Responses to Novartiss First Set of Interrogatories (Nos. 1-3)(918 Patent) filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) (Entered: 09/07/2022) (2) |
| Sep 6, 2022 | 94 | NOTICE OF SERVICE of 1) Defendants Laurus Labs Ltd. and Laurus Generics Inc.'s Initial Disclosures Pursuant to Paragraph 3 of the Delaware Default Standard for Discovery and 2) Defendants Laurus Labs Ltd. and Laurus Generics Inc.'s Rule 26(a)(1) Initial Disclosures filed by Laurus Generics Inc., Laurus Labs Limited.(Poff, Adam) (Entered: 09/06/2022) (3) |
| Sep 6, 2022 | 95 | NOTICE OF SERVICE of (1) Defendants Dr. Reddys Laboratories inc. and Dr. Reddys Laboratories, Ltd.s Initial Disclosures Pursuant to Fed. R. Civ. P. 26(a)(1) and (2) Defendants Dr. Reddys Laboratories inc. and Dr. Reddys Laboratories, Ltd.s Discovery Disclosures Pursuant to the District of Delawares Default Standard filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Dr. Reddys Laboratories, Ltd..(Stamoulis, Stamatios) (Entered: 09/06/2022) (2) |
| Aug 29, 2022 | 92 | SCHEDULING ORDER: Joinder of Parties due by 1/5/2023. Amended Pleadings due by 1/5/2023. Fact Discovery completed by 6/16/2023. Joint Claim Construction Brief due by 3/31/2023. A Markman Hearing is set for 4/14/2023, at 9:00 AM in Courtroom 6A. A Pretrial Conference is set for 2/2/2024, at 9:00 AM in Courtroom 6A. A 7 day Bench Trial is set to start 2/12/2024, at 8:30 AM in Courtroom 6A (see Order for further details). Signed by Judge Richard G. Andrews on 8/29/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) (Entered: 08/29/2022) (18) |
| Aug 26, 2022 | 91 | PROPOSED Scheduling Order, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 8/29/2022 (nms). (Entered: 08/26/2022) (18) |
| Aug 10, 2022 | 90 | NOTICE of Appearance by Alexis Stombaugh on behalf of Laurus Generics Inc., Laurus Labs Limited (Stombaugh, Alexis) (Entered: 08/10/2022) (3) |
| Aug 9, 2022 | 89 | NOTICE OF SERVICE of (1) Novartis's First Set of Interrogatories to Defendants (Nos. 1-3) and (2) Novartis's First Set of Requests to Defendants for the Production of Documents and Things filed by Novartis Pharmaceuticals Corporation.(Joyce, Alexandra) (Entered: 08/09/2022) (7) |
| Aug 3, 2022 | N/A | Scheduling Conference (0) Docket Text: Minute Entry for proceedings held before Judge Richard G. Andrews - Scheduling Conference held on 8/3/2022. Counsel for Plaintiff: D. Silver. Counsel for Defendants: E. Ormerod, A. Poff, R. Weinblatt, C. Hitch, D. Gattuso, B. Palapura, J. Seaman. Plaintiff is directed to submit the revised order. (Court Reporter Heather Triozzi.) Associated Cases: 1:22-cv-00032-RGA et al.(lak) |
| Jul 27, 2022 | 88 | Redacted Document (10) Docket Text: REDACTED VERSION of [85] Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 7/28/2022 (nms). |
| Jul 21, 2022 | N/A | Oral Order (0) Docket Text: ORAL ORDER: A Scheduling Conference is now set for 8/3/2022, at 2:00 PM in Courtroom 6A. Ordered by Judge Richard G. Andrews on 7/21/2022. Associated Cases: 1:22-cv-00032-RGA et al.(nms) |
| Jun 15, 2022 | 84 | Proposed Order (19) Docket Text: PROPOSED Scheduling Order (with disputed provisions), by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/15/2022 (nms). |
| Jun 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 629 in 20-md-2930-RGA; D.I. 83 in 21-cv-1330-RGA) STIPULATION and Proposed Order Extending Time to submit a Proposed Scheduling Order to June 15, 2022. Signed by Judge Richard G. Andrews on 6/13/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) |
| Jun 10, 2022 | 83 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION and Proposed Order Extending Time to submit a Proposed Scheduling Order to June 15, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 6/13/2022 (nms). |
| Jun 9, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 621 in 20-md-2930-RGA; D.I. 82 in 21-cv-1330-RGA) STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to June 10, 2022. Signed by Judge Richard G. Andrews on 6/9/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) |
| Jun 9, 2022 | 82 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to June 10, 2022 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Ormerod, Eve) |
| Jun 2, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 81 in 21-cv-1330-RGA; D.I. 604 in 20-md-2930-RGA) STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent No. 11,096,918 to June 8, 2022. Signed by Judge Richard G. Andrews on 6/2/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) |
| Jun 1, 2022 | 81 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION TO EXTEND TIME the parties' deadline to submit a Proposed Scheduling Order in this action concerning U.S. Patent No. 11,096,918 in accordance with the Court's oral order at the April 21, 2022 status conference to June 8, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 26, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 591 in 20-md-2930-RGA; D.I. 80 in 21-cv-1330-RGA) STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order concerning U.S. Patent No. 11,096,918 to June 1, 2022. Signed by Judge Richard G. Andrews on 5/26/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) |
| May 25, 2022 | 80 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in this action concerning U.S. Patent No. 11,096,918 in accordance with the Court's oral order at the April 21, 2022 status conference to June 1, 2022 - filed by Novartis Pharmaceuticals Corporation. (Silver, Daniel) |
| May 19, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (79 in 1:21-cv-01330-RGA, 582 in 1:20-md-02930-RGA) Joint STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to May 25, 2022 filed by Hetero USA Inc.,, Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. Signed by Judge Richard G. Andrews on 5/19/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) |
| May 18, 2022 | 79 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to May 25, 2022 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Ormerod, Eve) Modified on 5/19/2022 (nms). |
| May 11, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 569 in 20-md-2930-RGA; D.I. 78 in 21-cv-1330-RGA) STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order to May 18, 2022. Signed by Judge Richard G. Andrews on 5/11/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) |
| May 11, 2022 | 78 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION TO EXTEND TIME for parties to submit a Proposed Scheduling Order to May 18, 2022 - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd., Hetero USA Inc.,. (Ormerod, Eve) |
| May 5, 2022 | N/A | CORRECTING ENTRY: (0) Docket Text: CORRECTING ENTRY: The stipulation filed at D.I. 77 on 5/4/2022, has been removed from the docket. The filing lacked reference to the MDL it relates with. Counsel is to correct the omission and refile the stipulation accordingly. (nms) |
| May 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re (D.I. 77 in 21-cv-1330-RGA; D.I. 565 in 20-md-2930-RGA) STIPULATION and Proposed Order to Extend Time to submit a Proposed Scheduling Order in this action concerning U.S. Patent No. 11,096,918 to May 11, 2022. Signed by Judge Richard G. Andrews on 5/5/2022. Associated Cases: 1:20-md-02930-RGA, 1:21-cv-01330-RGA(nms) |
| May 5, 2022 | 77 | Stipulation to EXTEND Time (5) Docket Text: STIPULATION TO EXTEND TIME for the parties to submit a Proposed Scheduling Order in this action concerning U.S. Patent No. 11,096,918 in accordance with the Court's oral order at the April 21, 2022 status conference to May 11, 2022 - filed by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 4, 2022 | 75 | Order (4) Docket Text: SO ORDERED Granting [73] Stipulation and [Proposed] Order Dismissing Novartis' Motion to Dismiss Hetero's Counterclaims Against U.S. Patent No. 11,058,667 and Hetero's Counterclaims. Signed by Judge Richard G. Andrews on 5/4/2022. (nms) |
| May 4, 2022 | 76 | Order (4) Docket Text: SO ORDERED Granting [74] Stipulation and [Proposed] Order Dismissing Novartis' Motion to Dismiss Torrent's Counterclaims Against U.S. Patent No. 11,058,667 and Torrent's Counterclaims. Signed by Judge Richard G. Andrews on 5/4/2022. (nms) |
| May 3, 2022 | 73 | Stipulation (4) Docket Text: STIPULATION and [Proposed] Order Dismissing Novartis' Motion to Dismiss Hetero's Counterclaims Against U.S. Patent No. 11,058,667 and Hetero's Counterclaims by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| May 3, 2022 | 74 | Stipulation (4) Docket Text: STIPULATION and [Proposed] Order Dismissing Novartis' Motion to Dismiss Torrent's Counterclaims Against U.S. Patent No. 11,058,667 and Torrent's Counterclaims by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Apr 7, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Richard G. Andrews. Please include the initials of the Judge (RGA) after the case number on all documents filed. Associated Cases: 1:21-cv-01330-LPS et al. (ntl) |
| Apr 1, 2022 | 72 | Status Report (9) Docket Text: Joint STATUS REPORT by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Mar 29, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Reassigned to Judge Leonard P. Stark of the United States Court of Appeals for the Federal Circuit. Please include the initials of the Judge (LPS) after the case number on all documents filed. Associated Cases: 1:18-cv-01038-LPS et al. (ntl) |
| Mar 29, 2022 | N/A | Order (0) Docket Text: ORAL ORDER: The Court observes that this case is marked as related to one or more other cases now pending before another judge of this Court. Accordingly, IT IS HEREBY ORDERED that the parties shall meet and confer and, no later than April 1, submit a joint status report, providing their position(s) as to which judge this case should be reassigned to. ORDERED by Judge Leonard P. Stark on 3/29/22. (ntl) |
| Mar 15, 2022 | N/A | Create Case Association (0) Docket Text: Case associated with lead case: Create association to 1:20-md-02930-RGA. (ntl) |
| Jan 13, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [70] MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore and Attorney James E. Nealon filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc. Signed by Judge Leonard P. Stark on 1/13/22. (ntl) |
| Jan 13, 2022 | 70 | Motion for Leave to Appear Pro Hac Vice (5) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Steven J. Moore and Attorney James E. Nealon - filed by Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc.. (Dorsney, Kenneth) |
| Jan 6, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney A. Neal Seth and Corey Weinstein for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mal) |
| Jan 5, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [69] MOTION for Pro Hac Vice Appearance of Attorney A. Neal Seth, Esq. and Corey Weinstein, Esq. of Wiley Rein LLP filed by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc. Signed by Judge Leonard P. Stark on 1/5/22. (ntl) |
| Jan 5, 2022 | 69 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney A. Neal Seth, Esq. and Corey Weinstein, Esq. of Wiley Rein LLP - filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Attachments: # (1) Certification of A. Neal Seth, Esq., # (2) Certification of Corey Weinstein, Esq., # (3) Text of Proposed Order)(Seaman, John) |
| Jan 5, 2022 | 69 | Certification of A. Neal Seth, Esq. (1) |
| Jan 5, 2022 | 69 | Certification of Corey Weinstein, Esq. (1) |
| Jan 5, 2022 | 69 | Text of Proposed Order (1) |
| Dec 21, 2021 | 67 | Redacted Document (16) Docket Text: REDACTED VERSION of [63] Reply Brief, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/3/2022 (nms). |
| Dec 21, 2021 | 68 | Redacted Document (16) Docket Text: REDACTED VERSION of [64] Reply Brief, by Novartis Pharmaceuticals Corporation. (Silver, Daniel) Modified on 5/3/2022 (nms). |
| Dec 20, 2021 | 65 | Request for Oral Argument (2) Docket Text: REQUEST for Oral Argument by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc. re [37] MOTION to Dismiss for Failure to State a Claim Hetero's Counterclaims Against Novartis's U.S. Patent Nos. 9,517,226, 9,937,143, 11,135,192 AND 11,058,667. (Ormerod, Eve) |
| Dec 20, 2021 | 66 | Request for Oral Argument (2) Docket Text: REQUEST for Oral Argument, by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Ormerod, Eve) Modified on 5/3/2022 (nms). |
| Dec 13, 2021 | 61 | Main Document (23) Docket Text: REDACTED VERSION of [58] Answering Brief in Opposition, by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Attachments: # (1) Exhibit A-D)(Ormerod, Eve) |
| Dec 13, 2021 | 61 | Exhibit A-D (32) |
| Dec 13, 2021 | 62 | Main Document (23) Docket Text: REDACTED VERSION of [60] Answering Brief in Opposition, by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.. (Attachments: # (1) Exhibit A-D)(Ormerod, Eve) |
| Dec 13, 2021 | 62 | Exhibit A-D (32) |
| Dec 6, 2021 | 59 | Answer to Counterclaim (6) Docket Text: ANSWER to [46] Answer to Complaint, Counterclaim of Macleods Pharmaceuticals Ltd. and Macleods Pharma USA, Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Dec 1, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Christina Schwarz and Nicholas N. Kallas for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Dec 1, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher E. Loh for Novartis Pharmaceuticals Corporation added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Nov 30, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [49] MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham filed by Novartis Pharmaceuticals Corporation. Signed by Judge Leonard P. Stark on 11/30/21. (ntl) |
| Nov 30, 2021 | 56 | Redacted Document (24) Docket Text: REDACTED VERSION of [54] Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 30, 2021 | 57 | Redacted Document (24) Docket Text: REDACTED VERSION of [55] Stipulation, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 23, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [55] STIPULATION and [Proposed] Order Regarding Amended Briefing on Novartis's Motion to Dismiss Hetero's Counterclaims; [54] STIPULATION and [Proposed] Order Regarding Amended Briefing on Novartis's Motion to Dismiss Torrent's Counterclaims. Signed by Judge Leonard P. Stark on 11/23/21. (ntl) |
| Nov 22, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [51] MOTION for Pro Hac Vice Appearance of Attorney Dennies Varughese, Pharm.D., Esquire, Nirav N. Desai, Esquire, and Joseph H. Kim, Esquire filed by Laurus Labs Limited, Laurus Generics Inc. Signed by Judge Leonard P. Stark on 11/22/21. (ntl) |
| Nov 22, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Joseph H. Kim, Nirav N. Desai, Dennies Varughese, Pharm.D. for Laurus Generics Inc. and Laurus Labs Limited added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Nov 19, 2021 | 51 | Motion for Leave to Appear Pro Hac Vice (7) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Dennies Varughese, Pharm.D., Esquire, Nirav N. Desai, Esquire, and Joseph H. Kim, Esquire - filed by Laurus Generics Inc., Laurus Labs Limited. (Poff, Adam) |
| Nov 19, 2021 | 52 | Redacted Document (17) Docket Text: REDACTED VERSION of [38] Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 19, 2021 | 53 | Redacted Document (16) Docket Text: REDACTED VERSION of [41] Opening Brief in Support, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 18, 2021 | 50 | Answer to Counterclaim (13) Docket Text: ANSWER to [31] Answer to Complaint, Counterclaim by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 17, 2021 | 47 | Declaration (2) Docket Text: DECLARATION of Service of Macleods Pharmaceuticals Ltd. by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Nov 17, 2021 | 48 | Declaration (2) Docket Text: DECLARATION of Service of Macleods Pharma USA, Inc. by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) |
| Nov 17, 2021 | 49 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, and Jared L. Stringham)(Silver, Daniel) |
| Nov 17, 2021 | 49 | Certifications for Nicholas N. Kallas, Christina Schwarz, Christopher E. Loh, a (4) |
| Nov 15, 2021 | 43 | Notice of Appearance (2) Docket Text: NOTICE of Appearance by John M. Seaman on behalf of Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. (Seaman, John) |
| Nov 15, 2021 | 44 | Notice of Appearance (2) Docket Text: NOTICE of Appearance by April M. Kirby on behalf of Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd. (Kirby, April) |
| Nov 15, 2021 | 45 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Macleods Pharmaceuticals Ltd. for Macleods Pharma USA, Inc. filed by Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd.. (Seaman, John) |
| Nov 15, 2021 | 46 | Answer to Complaint (18) Docket Text: ANSWER to [1] Complaint,, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Macleods Pharmaceuticals Ltd., Macleods Pharma USA, Inc..(Seaman, John) |
| Nov 12, 2021 | 34 | Answer to Counterclaim (9) Docket Text: ANSWER to [20] Answer to Complaint and Counterclaims, by Novartis Pharmaceuticals Corporation.(Silver, Daniel) Modified on 5/3/2022 (nms). |
| Nov 12, 2021 | 35 | Answer to Counterclaim (11) Docket Text: ANSWER to [26] Answer to Complaint, Counterclaim of Dr. Reddy's Laboratories, Ltd. and Dr. Reddy's Laboratories, Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 12, 2021 | 36 | Answer to Counterclaim (9) Docket Text: ANSWER to [28] Answer to Complaint, Counterclaim of Laurus Labs Limited and Laurus Generics Inc. by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 12, 2021 | 37 | Main Document (2) Docket Text: MOTION to Dismiss Hetero's Counterclaims Regarding U.S. Patent Nos. 9,517,226, 9,937,143, 11,135,192 AND 11,058,667 - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Proposed Order)(Silver, Daniel) Modified on 5/3/2022 (nms). |
| Nov 12, 2021 | 37 | Proposed Order (1) |
| Nov 12, 2021 | 39 | Answer to Counterclaim (17) Docket Text: ANSWER to [22] Answer to Complaint,, Counterclaim, of Hetero USA Inc., Hetero Labs Limited, and Hetero Labs Limited Unit III by Novartis Pharmaceuticals Corporation.(Silver, Daniel) |
| Nov 12, 2021 | 40 | Main Document (2) Docket Text: MOTION to Dismiss for Failure to State a Claim Torrent's Counterclaims Against Novartis's U.S. Patent Nos. 9,517,226, 9,937,143, 11,135,192 AND 11,058,667 - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Proposed Order)(Silver, Daniel) |
| Nov 12, 2021 | 40 | Proposed Order (1) |
| Nov 12, 2021 | 42 | Answer to Counterclaim (17) Docket Text: ANSWER to [24] Answer to Complaint and Counterclaims, by Novartis Pharmaceuticals Corporation.(Silver, Daniel) Modified on 5/3/2022 (nms). |
| Nov 8, 2021 | 33 | Notice (Other) (3) Docket Text: NOTICE of Withdrawal of Beth A. Swadley by Laurus Generics Inc., Laurus Labs Limited (Poff, Adam) |
| Oct 29, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Kenneth S. Canfield for Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., and Torrent Pharmaceuticals Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Oct 28, 2021 | 31 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint, and COUNTERCLAIMS against All Plaintiffs, by Aurobindo Pharma USA Inc..(Hitch, Cortlan) Modified on 5/3/2022 (nms). |
| Oct 28, 2021 | 32 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Aurobindo Pharma Ltd. for Aurobindo Pharma USA Inc. filed by Aurobindo Pharma USA Inc.. (Hitch, Cortlan) |
| Oct 27, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Christopher D. Jones for Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (twk) |
| Oct 27, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [30] MOTION for Pro Hac Vice Appearance of Attorney Edward D. Pergament, Dmitry V. Shelhoff, Kenneth S. Canfield, and Julia Kim filed by Hetero USA Inc., Hetero Labs Limited, Hetero Labs Limited Unit III, Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. Signed by Judge Leonard P. Stark on 10/27/21. (ntl) |
| Oct 27, 2021 | 30 | Main Document (2) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Edward D. Pergament, Dmitry V. Shelhoff, Kenneth S. Canfield, and Julia Kim - filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Attachments: # (1) Certification, # (2) Certification, # (3) Certification, # (4) Certification)(Ormerod, Eve) |
| Oct 27, 2021 | 30 | Certification (1) |
| Oct 27, 2021 | 30 | Certification (1) |
| Oct 27, 2021 | 30 | Certification (1) |
| Oct 27, 2021 | 30 | Certification (1) |
| Oct 25, 2021 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorneys Bryan D. Beel and Autumn N. Nero for Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories, Ltd. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (srs) |
| Oct 22, 2021 | 20 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint, and COUNTERCLAIMS against All Plaintiffs, by Alkem Laboratories Ltd..(Dorsney, Kenneth) Modified on 5/3/2022 (nms). |
| Oct 22, 2021 | 21 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Alkem Laboratories Ltd.. (Dorsney, Kenneth) |
| Oct 22, 2021 | 22 | Main Document (39) Docket Text: ANSWER to [1] Complaint, and COUNTERCLAIMS against Novartis Pharmaceuticals Corporation, by Hetero Labs Limited Unit III, Hetero USA Inc., Hetero Labs Limited. (Attachments: # (1) Exhibits 1-4)(Ormerod, Eve) Modified on 5/3/2022 (nms). |
| Oct 22, 2021 | 22 | Exhibit 1-4 (70) |
| Oct 22, 2021 | 23 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Hetero Labs Ltd., Corporate Parent Hetero Drugs Ltd. for Hetero USA Inc. filed by Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc.. (Belgam, Neal) |
| Oct 22, 2021 | 24 | Main Document (39) Docket Text: ANSWER to [1] Complaint, and COUNTERCLAIMS against Novartis Pharmaceuticals Corporation, by Torrent Pharmaceuticals Ltd., Torrent Pharma Inc.. (Attachments: # (1) Exhibits 1-4)(Ormerod, Eve) Modified on 5/3/2022 (nms). |
| Oct 22, 2021 | 24 | Exhibit 1-4 (70) |
| Oct 22, 2021 | 25 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: No Parents or Affiliates Listed filed by Torrent Pharma Inc., Torrent Pharmaceuticals Ltd.. (Belgam, Neal) |
| Oct 22, 2021 | 26 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,, , COUNTERCLAIM against All Plaintiffs by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd..(Stamoulis, Stamatios) |
| Oct 22, 2021 | 27 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Dr. Reddy's Laboratories S.A. for Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd.. (Stamoulis, Stamatios) |
| Oct 22, 2021 | 28 | Answer to Complaint (30) Docket Text: ANSWER to [1] Complaint,, , COUNTERCLAIM against Novartis Pharmaceuticals Corporation by Laurus Generics Inc., Laurus Labs Limited.(Swadley, Beth) |
| Oct 22, 2021 | 29 | Disclosure Statement (4) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Laurus Labs Ltd. for Laurus Generics Inc. filed by Laurus Generics Inc.. (Swadley, Beth) |
| Oct 21, 2021 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [18] MOTION for Pro Hac Vice Appearance of Attorney Autumn N. Nero, Bryan D. Beel, and Christopher D. Jones filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd. Signed by Judge Leonard P. Stark on 10/21/21. (ntl) |
| Oct 21, 2021 | 19 | Declaration (2) Docket Text: DECLARATION of Service of Aurobindo Pharma Ltd., by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Oct 11, 2021 | 18 | Motion for Leave to Appear Pro Hac Vice (6) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Autumn N. Nero, Bryan D. Beel, and Christopher D. Jones - filed by Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd.. (Stamoulis, Stamatios) |
| Oct 8, 2021 | 7 | Return of Service Executed (2) Docket Text: Return of Service Executed by Novartis Pharmaceuticals Corporation. Aurobindo Pharma USA Inc. served on 10/7/2021, answer due 10/28/2021. (Silver, Daniel) |
| Oct 8, 2021 | 8 | Declaration (2) Docket Text: DECLARATION of Service of Alkem Laboratories Ltd., by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Oct 8, 2021 | 9 | Declaration (2) Docket Text: DECLARATION of Service of Dr. Reddy's Laboratories, Inc., by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Oct 8, 2021 | 10 | Declaration (2) Docket Text: DECLARATION of Service of Dr. Reddy's Laboratories, Ltd., by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Oct 8, 2021 | 11 | Declaration (2) Docket Text: DECLARATION of Service of Hetero Labs Limited Unit III, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Oct 8, 2021 | 12 | Declaration (2) Docket Text: DECLARATION of Service of Hetero Labs Limited, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Oct 8, 2021 | 13 | Declaration (2) Docket Text: DECLARATION of Service of Hetero USA Inc., Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Oct 8, 2021 | 14 | Declaration (2) Docket Text: DECLARATION of Service of Laurus Generics Inc., by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Oct 8, 2021 | 15 | Declaration (2) Docket Text: DECLARATION of Service of Laurus Labs Limited, by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Oct 8, 2021 | 16 | Declaration (2) Docket Text: DECLARATION of Service of Torrent Pharma Inc., by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Oct 8, 2021 | 17 | Declaration (2) Docket Text: DECLARATION of Service of Torrent Pharmaceuticals Ltd., by Novartis Pharmaceuticals Corporation. (Joyce, Alexandra) Modified on 5/3/2022 (nms). |
| Sep 22, 2021 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Leonard P. Stark. Please include the initials of the Judge (LPS) after the case number on all documents filed. (rjb) |
| Sep 20, 2021 | 1 | Main Document (49) Docket Text: COMPLAINT filed against Alkem Laboratories Ltd., Aurobindo Pharma Ltd., Aurobindo Pharma USA Inc., Dr. Reddy's Laboratories, Inc., Dr. Reddy's Laboratories, Ltd., Hetero Labs Limited, Hetero Labs Limited Unit III, Hetero USA Inc., Laurus Generics Inc., Laurus Labs Limited, Macleods Pharma USA, Inc., Macleods Pharmaceuticals Ltd., Torrent Pharma Inc., Torrent Pharmaceuticals Ltd. - Magistrate Consent Notice to Pltf. ( Filing fee $ 402, receipt number ADEDC-3702987.) - filed by Novartis Pharmaceuticals Corporation. (Attachments: # (1) Exhibit A, # (2) Civil Cover Sheet)(apk) |
| Sep 20, 2021 | 1 | Exhibit A (24) |
| Sep 20, 2021 | 1 | Civil Cover Sheet (3) |
| Sep 20, 2021 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (apk) |
| Sep 20, 2021 | 3 | ANDA Form (3) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: SEE ANDA FORM. Date of Expiration of Patent: 11/08/2026.Thirty Month Stay Deadline: 7/7/2023. (apk) |
| Sep 20, 2021 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 11,096,918. (apk) |
| Sep 20, 2021 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novartis AG for Novartis Pharmaceuticals Corporation filed by Novartis Pharmaceuticals Corporation. (apk) |
| Sep 20, 2021 | 6 | Main Document (2) Docket Text: Summons Issued with Magistrate Consent Notice attached as to Alkem Laboratories Ltd. on 9/20/2021; Aurobindo Pharma Ltd. on 9/20/2021; Aurobindo Pharma USA Inc. on 9/20/2021; Dr. Reddy's Laboratories, Inc. on 9/20/2021; Dr. Reddy's Laboratories, Ltd. on 9/20/2021; Hetero Labs Limited on 9/20/2021; Hetero Labs Limited Unit III on 9/20/2021; Hetero USA Inc. on 9/20/2021; Laurus Generics Inc. on 9/20/2021; Laurus Labs Limited on 9/20/2021; Macleods Pharma USA, Inc. on 9/20/2021; Macleods Pharmaceuticals Ltd. on 9/20/2021; Torrent Pharma Inc. on 9/20/2021; Torrent Pharmaceuticals Ltd. on 9/20/2021. (Attachments: # (1) Summons Issued, # (2) Summons Issued, # (3) Summons Issued, # (4) Summons Issued, # (5) Summons Issued, # (6) Summons Issued, # (7) Summons Issued, # (8) Summons Issued, # (9) Summons Issued, # (10) Summons Issued, # (11) Summons Issued, # (12) Summons Issued, # (13) Summons Issued)(apk) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
| Sep 20, 2021 | 6 | Summons Issued (2) |
